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Abstract
Objective Chordomas of the skull base have high recurrence
rates even after radical resection and adjuvant radiotherapy.
We evaluate the long-term clinical outcome using multidisci-
plinary management in the treatment of clival chordomas.
Methods Between 1984 and 2015, 22 patients diagnosed with
an intracranial chordoma were treated at the Karolinska
University Hospital, Stockholm, Sweden. Sixteen of 22 were
treated with Gamma Knife radiosurgery (GKRS) for tumour
residual or progression during the disease course. Seven of 22
received adjuvant fractionated radiotherapy and 5 of these also
received proton beam radiotherapy.
Results Fifteen of 22 (68%) patients were alive at follow-up
after a median of 80 months (range 22–370 months) from the
time of diagnosis. Six were considered disease free after >10-
year follow-up. The median tumour volume at the time of
GKRS was 4.7 cm3, range 0.8–24.3 cm3. Median prescription
dose was 16 Gy, range 12–20 Gy to the 40–50% isodose
curve. Five patients received a second treatment with GKRS
while one received three treatments. After GKRS patients
were followed with serial imaging for a median of 34 months
(range 6–180 months). Four of 16 patients treated with GKRS
were in need of a salvage microsurgical procedure compared
to 5/7 treated with conventional or proton therapy.
Conclusion After surgery, 7/22 patients received convention-
al and/or photon therapy, while 15/22 were treated with GKRS
for tumour residual or followed with serial imaging with
GKRS as needed upon tumour progression. With this multi-
disciplinary management, 5- and 10-year survivals of 82%
and 50% were achieved, respectively.
Keywords Chordoma .Microsurgery . Endonasal .
Transsphenoidal . GammaKnife radiosurgery . Skull base
Introduction
Intracranial chordomas are rare tumours arising extraduraly in
the clivus andmidline structures of the skull base and the yearly
incidence is no more than 0.1/1000.000 [35]. Histopathological
features of the tumours indicate remnants of the notochord as
the origin [46]. Recent gene expression studies analysing
cytokeratins and brachyury proteins further strengthen this the-
ory [52, 60]. Although considered low-grade malignancies,
these tumours are locally aggressive with invasive growth with-
in mesenchymal-derived tissues and a high risk of eventual
demise.
Microsurgery, with the aim of gross total (GTR) or subtotal
(STR) resection, followed by radiotherapy is considered the
standard treatment for clivus chordomas [19, 22, 42, 49, 51].
Most chordoma patients are treated with transsphenoidal
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resection [14, 16, 23, 28, 50, 54], although more extensive tu-
mours require transbasal or transpetrosal approaches [1]. Since
only retrospective case series are available in literature, the war-
rants for microsurgery and adjuvant radiotherapy are weak.
It is well accepted that these centrally located tumours in
the skull base are often impossible to radically removewithout
high risk of causing neurological deficits [18, 44, 56].
Chordomas are usually surrounded by invading cells in sur-
rounding bone and recurrences are frequent even after pre-
sumed radical surgery. Still, our current knowledge of
chordomas forms a hermeneutic rationale for a combination
of microsurgery and adjuvant radiation. Chordomas respond
poorly to conventional radiotherapy [36, 62], and therefore
linear accelerator (LINAC)-based fractionated stereotactic ra-
diotherapy (FSRT) [10] intensity-modulated radiation therapy
(IMRT) [45] and proton-beam radiotherapy [2–4, 20, 21, 37,
39, 40] have been used. Gamma Knife radiosurgery (GKRS)
has a potential to control tumours with poor radiation sensi-
tivity and has, accordingly, also been reported to offer an
effect on chordomas [19, 22, 26, 27, 33, 38, 53].
Due to the rarity of chordomas, even large centres deal with
a small number of patients each year. Neurosurgical and on-
cological management has evolved gradually [2], driven by
local resources and facilities. Major management differences
are possible in spite of widespread consensus regarding sur-
gery, the natural history and the need of adjuvant non-surgical
treatment. Large-scale prospective studies may be of benefit,
but in the past and in the foreseeable future, scientific warrant
for chordoma management must rely on critical analyses of
available retrospective data.
Our understanding of the present consensus is that most spe-
cialists agree on three points: (1) Bsafe^microsurgery is indicat-
ed for all patients, although small, histopathologically verified
tumours can be treated with only stereotactic radiosurgery
(SRS) [19, 26, 27, 53], (2) despite extensive surgical removal
and adjuvant treatment, tumour recurrence/progression is com-
mon, and (3) chordomas require adjuvant treatment following
initial therapy, often in close proximity to the index surgery [5].
Three issues are controversial: (1) Should radiation therapy
be initiated in close proximity to index surgery, or at a later
stage? (2) Is there a difference between response to photons
versus heavy particles, or are the total dose, fractionation and
dosimetric distribution of main importance? (3) Should SRS be
used as a complement to microsurgery or as salvage therapy in
case of progressive tumour growth?
The resources and healthcare organisation of our catchment
area have provided an infrastructure that has led to manage-
ment that differs somewhat from the consensus outlined
above, especially regarding early radiotherapy. In addition,
the invention and early development of GKRS [30, 31] at
our centre have provided easy access for patients with
radiosurgically accessible lesions, such as clival chordomas.
We report the long-term results of microsurgery and adjuvant
treatments, with emphasis on close follow-up and the use of
GKRS, for patients with intracranial chordomas treated con-
secutively between 1984 and 2015 at Karolinska University
Hospital, Stockholm, Sweden. The main aim is to determine
whether this management provides similar or different long-
term outcomes than management strategies that include early
heavy-particle radiation following gross total removal.
Methods
Demographic characteristics
From 1984–2015, 27 consecutive patients with a preliminary
histopathological diagnosis of intracranial chordomas were
treated at the Karolinska University Hospital, Stockholm,
Sweden. Of these, five patients were excluded from further
analyses; three patients were referred from abroad for comple-
mentary GKRS after initial microsurgical treatment in their
country of origin and were subsequently lost to follow-up,
while two patients were excluded when the review of patho-
logical diagnosis revealed that their tumours were in fact
chondrosarcomas (Table 1). The remaining 22 patients were
all treated with microsurgery as first-line treatment at the
Karolinska University Hospital (n = 15) or at one of the refer-
ring neurosurgical centres in Sweden (n = 7), allowing for a
definitely confirmed histopathological diagnosis following re-
examination, renewed immunohistochemistry and diagnosis
confirmation.
Maximal safe cyto-reductive microsurgery was the goal for
the initial treatment, although biopsies were only performed in
two patients. Surgical approaches were tailored according to the
location and relation of the tumour to critical neurovascular
structures. Altogether 55 microsurgical treatments were per-
formed for the 22 patients (range 1–8 procedures per patient).
The transsphenoidal approach was the most common approach
(17 of 55), followed by the pterional/orbitozygomatic (10 of
55), combined infra- and supratentorial (5 of 55), transbasal
(4 of 55) and suboccipital/retrosigmoidal (3 of 55).
Complications after surgery were classified [29] according to
Ibanez et al., where Ibanez grade I represents any non-life-
threatening complication treated without invasive procedures,
grade II is complications requiring invasive management, grade
III is life-threatening adverse events requiring treatment in an
intensive care unit (ICU) and grade IV is deaths as a result of
complications.
Gamma Knife radiosurgery
GKRS was performed in 16 out of 22 patients at a median
time of 22 (range, 7–116) months after the first microsurgical
treatment. No patients received GKRS prior to microsurgery.
Since none of the microsurgery was considered radical, the
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indication for GKRS was tumour recurrence/progression after
watchful waiting with serial imaging (n = 10) or treatment of
the tumour residual (n = 6). Ten patients received one GKRS
treatment; five patients two GKRS treatments, while one pa-
tient received three GKRS treatments. The GKRS procedure
has been described previously [31, 57]. Briefly, a Leksell ste-
reotactic frame (G-frame) and Leksell Gamma Knife®,
models B and C (Elekta, Stockholm, Sweden) were used. In
2009, the latest version of the Gamma Knife, Perfection™,
was installed and has been used since. The stereotactic frame
was applied under local anaesthesia, following administration
of oral benzodiazepine. Stereotactic MRI was used for dose
planning in all patients, although the MRI sequences have
changed over the years. Fourteen of the Gamma Knife proce-
dures were performed with Leksell Gamma Plan®, (Elekta,
Stockholm, Sweden), while five procedures between 1990
and 1993 were carried out with the Kula dose planning soft-
ware system (Elekta, Stockholm, Sweden). The median target
volume was 4.7 cm3 (range 0.8–24.3 cm3). The median pre-
scription dose was 16 Gy (range 12–20 Gy). The median
maximum dose to the tumour volume was 36 Gy (range 28–
50 Gy). After the Gamma Knife treatment the stereotactic
frame was removed and the patients were discharged after a
few hours of observation.
Regarding radiation treatment: (1) GKRS was the most
frequently implemented radiation modality, (2) five patients
were treated with proton beam radiotherapy, which was deliv-
ered as a combination of fractionated combined proton and
photon radiation therapy, and (3) two patients were treated
with fractionated radiotherapy (FRT) at a total dose of 50–
54 Gy in fractions of 1.8–2.0 Gy.
Follow-up
The patients were followed clinically for a median of
80 months (range 22–370 months) after index microsurgery.
Radiologically, patients were followed with MRI for a median
of 77months (range 12–311months). The post-operativeMRI
was performed within 3 months after surgery and then annual
MRI controls were performed for a period of 5 years, after
which an individual follow-up plan was tailored. The result of
microsurgery was classified as GTR (no visible residual), STR
(visible residual approximately <5% of original tumour size
on contrast-enhanced MRI), partial removal (visible residual,
5–50% of original tumour size) or biopsy (visible residual
>50% of original tumour size). Any increase in tumour vol-
ume was considered a Btumour recurrence/progression^ and
patients were subsequently evaluated at a multidisciplinary
conference for possible additional treatment. The tumor vol-
ume wasmeasured on LGP software or estimated by measur-
ing the tumour radius (r) in three dimensions on MR sections
(using the formula V = 4/3π × r1 × r2 × r3). Images that
allowed exact measurements at diagnosis were unavailable
for five patients. For this reason, we also classified tumours
as small (≤3 cm in maximal diameter) or large (> 3 cm), since
this information was available for all patients. In the 17 pa-
tients receiving GKRS, follow-up after the initial GKRS treat-
ment ranged from 6 to 180 months (median of 34 months).
Overall survival (OS) after diagnosis was the primary end-
point. Results are reported as cumulative survival plots with
estimates of median and mean survival.
Ethics
The study was approved by the regional ethical committee in
Stockholm, Sweden (no. 2016/1497–31/4).
Results
Patients, surgical outcome and overall survival
At the time of diagnosis, the median age of the patients
(n = 22) was 48 years (range 14–79 years), and 11 were male.
The median Karnofsky Performance Status (KPS) score was
90 (range 60–100). Cranial nerve palsy was the most frequent
objective finding, with 12/22 patients experiencing diplopia; 7
of these were caused by abducens nerve palsy, 3 by oculomo-
tor nerve palsy and 2 by trochlear nerve palsy.
Twenty-one patients in this study were initially treated with
microsurgical resection, while in two patients, transsphenoidal
biopsy was performed as an initial diagnostic procedure,
followed, however, by GTR in one patient. At the time of
index surgery, the median tumour volume was 14 cm3 (range
0.9–75.0 cm3). We assessed the primary surgical outcome as
GTR in 3 patients, STR in 12, partial in 6 and biopsy only in 1
case. Of those having the index surgery performed at our
institution (n = 15), three improved neurologically after the
surgery, with eight experiencing no change in their clinical
status. Five of the operated patients experienced temporary
deterioration in their neurological state, most often caused
by cranial nerve palsies (4 out of 5 patients), which became
permanent in two patients. Two experienced CSF leakage, of
which one developed meningitis (complication grade II accord-
ing to Ibanez). Two of the patients operated transsphenoidally
developed pituitary deficiency (complication grade I according
to Ibanez). Furthermore, one patient experienced an aggrava-
tion of previous respiratory failure necessitating intensive care
(complication grade III according to Ibanez), while another
experienced a postoperative haemorrhage requiring surgical in-
tervention and intensive care treatment (complication grade III
according to Ibanez). No peri-operative mortality, defined as
death within 30 days after surgery, was seen in this series.
Overall 5- and 10-year survival after diagnosis was 82%
(14/17 patients) and 50% (6/12 patients), respectively.
Three of nine (33%) patients survived more than 15 years.
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A Kaplan-Meier analysis revealed a median survival time
of 196 months (CI 95% 3.5–388.5 months). Fifteen of 22
patients were alive at the time of follow-up, thus presenting
an overall survival of 68%. Seven of 22 patients died dur-
ing follow-up. Tumour progression was considered the
cause of death in all but one patient who died from a radi-
ation complication (patient no. 3). See Table 1 and Fig. 1
for more details.
Gamma Knife treatment
Of the 16 patients treated with GKRS, tumour control was
achieved in 50% (8/16 patients) after the first GKRS treat-
ment, with a median follow-up time of 34 months (range 6–
180 months) after GKRS. The GKRS procedure was per-
formed at a median of 22 (range 7–116) months after initial
surgery. Kaplan-Meier analyses estimated a median tumour
control of 34 months (95% CI 0–70 months). Loss of TC after
GKRS was seen in 8/16 cases after the first GKRS (Fig. 2).
After the first GKRS treatment, TC was achieved in 8/16
patients at 6 months (n = 1), 2–5 years (n = 3) and 8–15 years
(n = 4), while recurrences were detected in 8/16. Four of these
eight patients received a salvage microsurgical procedure at a
median of 45 months after the initial GKRS, while the remain-
ing four were treated with additional GKRS only. Of the re-
current tumours in eight patients, all grew outside of the initial
GKRS prescription dose volume, while one recurrence was
Bin field^. An adverse radiation effect (ARE), seen as local
edema or cranial nerve palsy, was seen in 3/16 patients treated
with GKRS (Table 2). Six of the eight patients with failed
radiosurgical control received additional GKRS. After the sec-
ond GKRS, one patient had TC at 6-month follow-up, two had
out-of-field recurrences at 21 and 2 months, respectively, and
the remaining three patients had in-field tumour recurrence
after 16–24 months.
Fractionated radiation and proton beam therapy
Seven of 22 patients received postoperative conventional FRT
and/or proton beam radiotherapy (45–55 Gy). Proton beam
radiotherapy was delivered as a salvage treatment following
repeated surgeries during a course of 84months in one (patient
no. 2) and as adjuvant treatment after partial or STR removal
in three patients (nos. 1, 3, 16) and after biopsy in one patient
(no. 22). Patient no. 2 experienced tumour recurrence after
32 months, patient no. 1 after 51 months and patient no. 16
after 31 months. In patient no. 22, harbouring a chondroid
chordoma (proliferation index 1%), TC was achieved at
123 months and TC was also achieved in patient no. 3, who
died from radiation complications. Patient no. 3 developed an
edema in the brainstem 18 months after the proton beam ra-
diotherapy and deteriorated neurologically with hemi-paresis,
confusion and blurred consciousness. The edema was consid-
ered an adverse radiation effect (RTOG grade 5) and the pa-
tient died 12 months later. Two patients received FRT as part
of the initial treatment (no. 5) or as salvage therapy after re-
currence (no. 13). Patient no. 5 had tumour recurrences treated
with microsurgery and GKRS after 60 and 70 months, respec-
tively, while patient no. 13 died from tumour progression
41 months after FRT. In patients treated with FRT or proton
Fig. 1 Kaplan-Meier analysis of
survival after diagnosis
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beam radiotherapy five of seven patients experienced a recur-
rence(s) necessitating salvage micro- and/or radiosurgery
(Table 1).
Long-term tumour control
Our long-term figures allowed identification of six patients who
did not show sign of residual disease, with tumour control
>10 years (120–370 months) after treatment, which may con-
tradict the belief that all chordomas recur if you allow for suf-
ficiently long follow-up. Among the patients considered dis-
ease-free, three patients are still alive, two died from unrelated
causes 120 and 293 months after treatment, respectively, while
one was lost to follow-up after 10 years. Three of these patients
underwent STR followed by GKRS, one underwent STR
followed by FRT, another underwent GTR without any adju-
vant treatment, and the last one with a histologically non-
aggressive (chondroid chordoma, proliferation index 1%) small
tumour underwent biopsy and proton-beam RT.
Discussion
Our findings suggest (1) that adjuvant radiation therapy can be
postponed or even replaced by GKRS for potential residuals
or follow-up with serial imaging and GKRS treatment of re-
currences, (2) radical surgery is not a prerequisite for long-
term tumour control, (3) SRS can be used to control chordoma
residuals or recurrences and to avoid repeated microsurgery,
and (4) there is no obvious qualitative difference in biological
response between photon- and proton-based RT.
Timing of adjuvant RT and long-term survival
Our treatment results do not agree with the belief that early
adjunctive radiotherapy is necessary in chordoma manage-
ment. Our management comprised serial imaging follow-up
with GKRS as needed upon recurrence or GKRS due to tu-
mour residual after index microsurgery in 17/22 patients; it
showed similar or even superior overall survival than reported
in studies on maximal safe surgery followed by immediate
adjuvant radiation therapy for clival chordomas. During fol-
low-up, additional micro- or GKRS was used in case of tu-
mour recurrence and/or progression. In the present study 5-
year overall survival was 82%. This result is better than the
mean overall 5-year survival of 54% for series with immediate
adjuvant photon radiotherapy and similar to the 80–82%
found in series implementing proton-beam, ion-particle or ste-
reotactic radiation therapy [2]. Other researchers report worse
long-term outcomes than Amichetti et al. Registry data from
the UK [59] showed 56% 5-year survival and a recent system-
atic review showed an estimated 5- and 10-year survival of
63% and 16%, respectively [24]. Our 10-year survival of 50%
compares equally with the best reported 10-year survival of
54% following proton beam [37] and 56% following surgery
+ GKRS. Furthermore, some reported series fail to differenti-
ate between low-grade chondrosarcomas and chordomas [20]
[37]. Mixed survival data will show falsely optimistic tumour
control rates, since low-grade chondrosarcomas have a
Fig. 2 Kaplan-Meier analysis of
tumour control after Gamma
Knife radiosurgery
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different and more benign course [1, 13, 15, 33]. Our data
show that individual treatments were successful in a majority
of patients, but also that we were unable to achieve long-term
tumour control in a third of our patients.
Surgical radicality and long-term tumour control
Although aiming for a safe maximal cytoreductive surgery for
the initial treatment of patients with skull base chordoma,
several reports on chordoma resection report a high number
of surgical complications [1, 47, 56]. As chordomas progress,
bony structures of the cranial base are destructed, the dura
often becomes infiltrated and cranial nerves, and blood vessels
will be enveloped. To achieve an STR or GTR of the
chordoma in this situation, a combined or a staged resection
is frequently needed [18, 34]. We used staged approaches in 7
of 12 patients with large tumours and 1 of 10 patients with a
small tumour. We still considered risks associated with radical
removal of infiltrated tumour margins as too high.
Accordingly, these procedures could not be considered radical
even with GTR achieved. We found many new neurological
deficits (25%) after surgery, but only 12% became permanent.
No deficit resulted in loss of independence (Karnoffsky <70).
Less aggressive surgery correlates with low morbidity in cav-
ernous sinus meningiomas [17]. We consider our results neu-
rologically favourable, but only 3 patients underwent GTR, 12
had STR and 7 had 50% removal. Non-radical surgery is less
aggressive, but usually increases risks of recurrence.
Unexpectedly, our long-term figures allowed identification
of six patients who we consider disease-free after >10-year
follow-up. However, five out of six of these patients were
treated with more aggressive surgery, indicating that maximal
tumour removal is important for long-term tumour control.
The extradural and midline origin of chordomas makes a
midline approach ideal for these tumours. In earlier reports,
and also in the first cases of this series, an anterior transbasal
approach was used [7, 11]. The development of endoscopic
techniques during the last years has made the endonasal
transsphenoidal approach the preferred choice for the index
surgery [12, 14, 25, 28, 50]. It is technically easier to achieve
extensive removal with other than transsphenoidal ap-
proaches, but our tumour control, when implementing
Table 2 Gamma Knife radiosurgery treatment data
Patient no. Year of
GKRS
Indication for GKRS
(tumour residual or
tumour recurrence)
GKRS
Tumour
Volume
cm3
Prescription
dose (Gy)/
max dose
(Gy)
Isodose TC/
LTC (in or
out of the
radiation field)
Follow-up time
(months)/
time to LTC
(months)
ARE
1 2010 Residual 8.1 16/32 50 LTC/out of field 34 No
2013 Recurrence 2.0 16/32 50 LTC/in field 19 No
2 2005 Residual 1.3 15/30 50 LTC/out of field 55 No
2010 Recurrence 16.3 18/36 50 LTC/out of field 21 Yes
4 2010 Recurrence 3.7 18/36 50 TC 61 Yes
5 1990 Recurrence 6.0 20/40 50 TC 180 No
6 2008 Recurrence 4.7 19/38 50 TC 46 No
8 1992 Residual 6.0 12/30 40 TC 168 No
9 2002 Recurrence 2.1 20/40 50 TC 103 No
10 2005¤ Recurrence 2.2 14/28 50 LTC/ out of field 22 No
2007¤ Residual NA ND ND LTC/ out of field LF No
2008 Recurrence 11.4 16/36 45 LTC/out of field LF No
12 1993 Recurrence NA 12/50 ND LTC/out of field 33 Yes
1996 Recurrence 24.3 15/38 40 LTC/in field 24 No
13 1996 Residual 5.1 14/35 40 LTC/out of field 21 No
14 1996 Recurrence 17.2 15/38 40 LTC/out of field 15 No
15 2006 Recurrence 2.0 16/32 50 TC 94 No
17 2010 Residual 9.2 16/29 55 TC 27 No
18 2015 Residual 4,0 18/36 50 TC 6 No
19 2013 Recurrence 16.0 18/36 50 LTC/out of field 24 No
2015 Recurrence 4.0 18/36 50 TC NA No
21 2012 Recurrence 2,5 18/36 50 LTC/out of field 13 No
2013 Recurrence 0,8 18/36 50 LTC/ in field 16 No
Abbreviations: GKRS Gamma Knife radiosurgery, TC tumour control, LTC loss of tumour control, ARE adverse radiation effect, NA not available, LF
lost to follow-up
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transsphenoidal approach in combination with GKRS was
comparable to when more extensive surgical approaches were
used.Both strategies appeared to offer long-term tumour con-
trol and even cure in some patients. It is inevitable that micro-
surgical techniques will develop further and allow better mi-
crosurgical radicality without aggravating morbidity. Tamura
et al. recently reported long-term results from extensive mi-
crosurgery followed by GKRS for recurrences [53]. They re-
port 10- and 15-year survival rates of 72%, which is high
compared to our results and the previous literature. Their sur-
gical approach was more radical than ours, however, with
notably higher complication rates. In accordance with our
own strategy and results, Tamura et al. also followed their
patients closely and re-treated when recurrences appeared.
The management of these tumours as chronic diseases with
close follow-up and readiness to re-treat is another important
factor that seemingly improved long-term control and
survival.
A final area of uncertainty is tumour biology. The biolog-
ical behaviour varied between apparent cures in 25% of pa-
tients to death from intractable tumours in another 25%. This
indicates a biological heterogeneity among chordomas.
Proliferation indices varied widely in the few patients where
it was analysed, and it also appeared that our two patients with
chondroid chordomas did extraordinarily well. In agreement,
particularly favourable outcomes for chondroid chordomas
have been reported by others [6, 41]. The biological behaviour
is thus not predictable from the diagnostic label Bchordoma^.
Proliferation indices, genotypic and phenotypic markers may
allow prognostic sub-classification to determine therapeutic
choices and clinical prognosis [22].
Role of Gamma Knife radiosurgery and radiotherapy
in chordoma treatment
In our cohort, radiation therapy was not given as an adjuvant
therapy after first surgery. Instead small remnants of
chordomas were treated with GKRS, as described in other
chordoma series [22, 53]. FRT or proton beam radiotherapy
was reserved as salvage treatment in case of tumour progres-
sion or recurrences after microsurgery and GKRS. With this
treatment strategy, fractionated radiotherapy, which can usu-
ally only be administered once, could be saved until a later
stage of the disease and was not necessary for most (15/22) of
our patients.
A tumour control of 50% after the first GKRS, for a median
follow-up time of 34 months, represents results in the lower
end compared with previous published reports on GKRS use
for clival chordoma residuals and recurrences [9, 19, 22, 26,
32, 33, 53, 61]. However, after GKRS, only 4 of 16 patients in
this study needed new microsurgical treatment, which sug-
gests a role for GKRS in the management of clival chordomas.
The literature contains a number of retrospective case series
of microsurgery and adjuvant radiation. Our observations in-
dicated that to achieve tumour control or cure, one does not
necessarily need to implement immediate adjuvant photon or
proton beam radiotherapy. The control rates for GKRS for
chordoma residuals and tumour recurrences were similar or
better in our series than in chordoma series with other treatment
modalities, indicating that early radiosurgery of chordoma re-
siduals did not provide any clear benefit compared to our man-
agement with Bwait and scan^ followed by tailored treatment of
tumour recurrence if needed. In fact, three of four patients died
from tumour recurrences or radiation necrosis within a few
years after early proton beam treatment and half of the patients
in the present series needed additional microsurgery and/or
GKRS for recurrence within 5 years after early photon
radiotherapy.
Our recurrence rate was 50% following initial radiosurgery
in 16/22 patients. The recurrences occurred outside of the
treatment field in eight of nine patients, which again reflected
the infiltrative growth pattern of this locally aggressive tu-
mour. Our observations following additional recurrences sug-
gested gradual biological progression. Six of the eight patients
received additional GKRS treatments, and this time three of
six patients experienced tumour recurrence within the treat-
ment field, without the possibility for further treatment, ulti-
mately leading to death.
Possible qualitative differences of adjuvant radiation
To avoid recurrences, FRT has been used although several
reports indicate that conventional radiotherapy with a total
dose <45–55 Gy is of limited value [8, 43]. Proton beam
radiotherapy gives a steeper radiation gradient, which allows
doses of 60–80-Gy equivalents to the targeted chordoma, with
less risk of overdosing radiosensitive organs in the close vi-
cinity, such as the brainstem and the optic nerves [40, 58].
Early results after proton beam radiotherapy are promising,
but follow-up times are generally short in these series.
Subsequently, late recurrences, which are the rule for
chordomas, can go by undetected [48]. In a systematic review,
Amichetti et al. [2] concluded that proton beam radiotherapy
was superior to LINAC-based radiotherapy or radiosurgery
for clival chordoma radiotherapy [4, 20, 21, 37, 40] [3, 39].
It is unclear whether the benefit is argued to reflect dose dis-
tribution or qualitative aspects of protons compared to pho-
tons, although the latter is frequently suggested. There were,
however, methodological shortcomings in Amichetti’s sys-
tematic review: (1) no head-to-head comparative study on
chordomas treated with LINAC-based RT or proton beam
radiotherapy was included, (2) short follow-up times were
reported in the included studies, and finally (3) higher radia-
tion doses were usually used in the proton beam series (66–
83 Gy). With modern LINAC techniques intensity-modulated
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arc therapy is combined with multileaf collimators. With these
new technical developments, identical dose plans can usually
be achieved with fractionated, LINAC-based RT as for dose
plans for proton beam therapy. We therefore disagree with
Amichetti’s conclusion that proton RT is superior to LINAC-
based RT for clival chordomas. In agreement with our view,
LINAC treatment with higher radiation doses (60–70 Gy) pro-
duced results comparable to the proton series [10]. Hadron
therapy has been suggested to provide a qualitatively better
effect, but so far long-term data are lacking and short-term
data are similar to other modalities [48, 55]. Taken together,
neither previous studies nor observations in our material show
a qualitative difference in biological response between pho-
tons and protons. Instead, it appears that the dose distribution
and ability to deliver sufficient radiation to the actual tumour,
which is more readily done for small than large targets, deter-
mine the radiation response. In agreement, GKRS can be ex-
pected to be efficient for small circumscribed lesions because
of the sharp dose gradient and feasibility of high radiation
doses in the targeted tumour.
Strengths and limitations of the study
The standard limitations of retrospective observational studies
can also be identified in the present study. All retrospective
heterogeneous series reflect uncoordinated individual treat-
ment decisions determined by present states of knowledge
and an ambition to provide best available care to individual
patients. The lack of standardised treatment and small series
make many statistical comparisons and evaluations invalid. It
is, however, still possible to compare whether our results and
observations agree with general treatment recommendations
and beliefs—which also reflect an ambition to formulate the
best possible options. In addition, robust and objective end-
points are relevant. Also, our study has a strength in renewed
analyses of all tumour samples for confirmation of the diag-
nosis, which excluded two patients since pathological review
and renewed staining led to a reclassification of two tumours
as chondrosarcomas.
To avoid selection bias, all patients were included consecu-
tively, without excluding patients with short follow-up. To avoid
detection bias we used survival as the primary endpoint rather
than progression-free survival or neurological deterioration,
which are more subjective. Further, the long follow-up time in
this study insured the detection of late events. Symptom devel-
opment and side effects are more difficult variables and in this
study we were dependent on documented events in the patients’
charts. Still, the patients had their follow-up at our institution,
with the disease course documented in our own charts, which is
better than in many retrospective multicentre studies.
Unfortunately, median follow-up after GKRS was only
34 months in this series, and one has to suspect that later recur-
rences will emerge. A 3-year median follow-up after RT is,
however, common in the literature on this topic. The present
results on tumour control are comparable to RT reports with
similar follow-up time [10, 40, 48]. The small number of study
patients made regular statistical analysis impossible and results
have instead been reported as the proportion of the total number
of patients in the study.
Conclusion
In the present consecutive series, we report on multidisciplin-
ary management in a cohort of patients with clival chordomas,
with emphasis on the use of GKRS to treat tumour residuals or
as needed upon tumour recurrence. Overall survival for this
cohort was 68% (15/22), with a Kaplan-Meier estimation of
median survival at 196 months. Only 4/16 patients treated
with Gamma Knife later needed re-operation and 6 patients
were disease-free more than 10 years after the last treatment.
Our findings confirm previous reports in the literature in-
dicating that clival chordomas should be viewed as a chronic
progressive disease, with a continuous need to monitor and
deal with potential recurrences, irrespective of adjuvant radi-
ation. It is thus neither realistic nor rational to plan for a one-
time cure comprising maximal safe surgery and adjuvant ra-
diation [19, 22, 53]. Furthermore, our data suggest a beneficial
role for Gamma Knife treatment in the multidisciplinary man-
agement of clival chordomas.
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